Your browser is no longer supported. Please, upgrade your browser.
KNSA Kiniksa Pharmaceuticals, Ltd. monthly Stock Chart
KNSA [NASD]
Kiniksa Pharmaceuticals, Ltd.
Index- P/E- EPS (ttm)-3.03 Insider Own0.50% Shs Outstand59.08M Perf Week26.05%
Market Cap994.91M Forward P/E- EPS next Y-3.09 Insider Trans-20.63% Shs Float18.79M Perf Month-14.52%
Income-161.90M PEG- EPS next Q-0.66 Inst Own79.00% Short Float7.19% Perf Quarter50.49%
Sales- P/S- EPS this Y-43.60% Inst Trans-0.93% Short Ratio5.06 Perf Half Y124.53%
Book/sh4.11 P/B4.10 EPS next Y-6.90% ROA-54.40% Target Price29.33 Perf Year-5.92%
Cash/sh3.95 P/C4.26 EPS next 5Y- ROE-61.10% 52W Range5.01 - 21.50 Perf YTD52.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-21.67% Beta-
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low236.13% ATR2.11
Employees135 Current Ratio8.70 Sales Q/Q- Oper. Margin- RSI (14)57.45 Volatility14.94% 15.59%
OptionableNo Debt/Eq0.00 EPS Q/Q32.50% Profit Margin- Rel Volume1.69 Prev Close15.08
ShortableYes LT Debt/Eq0.00 EarningsMar 05 AMC Payout- Avg Volume267.26K Price16.84
Recom1.70 SMA2015.91% SMA505.14% SMA20042.00% Volume451,327 Change11.67%
Apr-01-20Initiated BofA/Merrill Buy $25
Mar-11-19Initiated Barclays Overweight $26
Dec-12-18Reiterated Wedbush Outperform $31 → $33
Jun-19-18Initiated JMP Securities Mkt Outperform $33
Apr-01-20 09:04AM  Company News for Apr 1, 2020 Zacks
Mar-31-20 08:15AM  Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation GlobeNewswire +26.68%
Mar-30-20 07:30AM  Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session GlobeNewswire
Feb-26-20 07:30AM  Kiniksa Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Recent Pipeline Activity GlobeNewswire
Feb-11-20 09:12AM  Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance Zacks
Feb-05-20 09:21AM  Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat Zacks
Jan-13-20 08:00AM  Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts GlobeNewswire
Dec-19-19 10:13AM  The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals Zacks
Dec-18-19 02:27PM  Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More Zacks
Dec-16-19 07:29AM  Did Hedge Funds Drop The Ball On Kiniksa Pharmaceuticals, Ltd. (KNSA) ? Insider Monkey
Dec-12-19 09:59AM  Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy Zacks
Dec-11-19 09:47AM  Goldman Sachs: The Good, the Bad and the Ugly of the Biotech Sector TipRanks
08:30AM  Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma GlobeNewswire
Dec-10-19 08:00AM  Kiniksa Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire +13.63%
Dec-07-19 07:07AM  We're Keeping An Eye On Kiniksa Pharmaceuticals's (NASDAQ:KNSA) Cash Burn Rate Simply Wall St.
Nov-21-19 10:22AM  Company News For Nov 21, 2019 Zacks
Nov-20-19 04:01PM  Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference GlobeNewswire +28.67%
08:00AM  Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis GlobeNewswire
Nov-16-19 12:00PM  Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 GlobeNewswire
Nov-12-19 04:01PM  Kiniksa Presents Preclinical Data on the Role of GM-CSF in GCA at the 2019 ACR/ARP Annual Meeting GlobeNewswire -7.91%
Nov-01-19 10:55AM  Were Hedge Funds Right About Selling Kiniksa Pharmaceuticals, Ltd. (KNSA)? Insider Monkey +5.82%
Oct-28-19 04:01PM  Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Oct-08-19 04:48AM  Kiniksa Pharmaceuticals Enters Oversold Territory Zacks
Sep-19-19 04:01PM  Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research GlobeNewswire
Aug-19-19 07:30AM  Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019 GlobeNewswire
Aug-12-19 04:02PM  Kiniksa Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
04:01PM  Kiniksa Announces Interim Data from KPL-716 Repeated-Single-Dose Phase 1b Clinical Trial GlobeNewswire
Aug-06-19 07:30AM  Kiniksa Pharmaceuticals to Present at the 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 07:30AM  Kiniksa Pharmaceuticals Announces Collaboration with the Myocarditis Foundation for the Pericarditis Community GlobeNewswire
Jun-29-19 06:17PM  Is Kiniksa Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ? Insider Monkey
Jun-12-19 07:30AM  Kiniksa Presents Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at the Annual European Congress of Rheumatology GlobeNewswire
Jun-10-19 11:26AM  The Kiniksa Pharmaceuticals (NASDAQ:KNSA) Share Price Is Down 23% So Some Shareholders Are Getting Worried Simply Wall St.
May-30-19 04:01PM  Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019 GlobeNewswire
May-29-19 04:01PM  Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire
May-16-19 07:30AM  Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research GlobeNewswire
May-13-19 07:30AM  Kiniksa Presents Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology GlobeNewswire
May-02-19 07:30AM  Kiniksa Reports First Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Apr-29-19 02:55PM  Is Pharmaceuticals, Ltd. (KNSA) A Good Stock To Buy ? Insider Monkey
Apr-23-19 06:00AM  Long-Term "GameChangers" in Biotech MoneyShow
Apr-17-19 04:25PM  Kiniksa to Present Clinical and Preclinical Data for KPL-716 at the 77th Annual Meeting of the Society for Investigative Dermatology GlobeNewswire
Apr-08-19 04:01PM  Kiniksa to Present KPL-404 Preclinical Data at the Keystone Symposia on Antibodies as Drugs GlobeNewswire -10.59%
Mar-18-19 07:30AM  Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiologys 68th Annual Scientific Session GlobeNewswire
Mar-07-19 07:30AM  Kiniksa Reports Fourth Quarter and Full-Year 2018 Financial Results and Highlights Recent Corporate and Pipeline Activity GlobeNewswire
Feb-28-19 07:30AM  Kiniksa Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference GlobeNewswire
Feb-26-19 07:30AM  Kiniksa Pharmaceuticals to Present at the Barclays Global Healthcare Conference GlobeNewswire
Jan-31-19 08:57AM  Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Public Offering GlobeNewswire
Jan-29-19 07:25AM  The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive Benzinga -13.78%
Jan-28-19 05:23PM  Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement GlobeNewswire
Jan-03-19 07:30AM  Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab GlobeNewswire
Dec-27-18 08:14AM  5 Best-Performing IPOs of 2018 Zacks
Dec-17-18 08:36AM  Kiniksa Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire -7.41%
Dec-11-18 07:30AM  Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial GlobeNewswire
Dec-06-18 08:00AM  Kiniksa Provides Update on U.S. FDA Review of Investigational New Drug Application for Mavrilimumab in Giant Cell Arteritis GlobeNewswire -6.92%
Nov-15-18 07:35AM  Detailed Research: Economic Perspectives on Knight-Swift Transportation, Benitec Biopharma, Eastern, Kiniksa Pharmaceuticals, Qualstar, and Nomura Holdings Inc ADR What Drives Growth in Today's Competitive Landscape GlobeNewswire +6.20%
Nov-01-18 08:00AM  Kiniksa Reports Third Quarter 2018 Financial Results and Pipeline Progress GlobeNewswire +5.72%
Sep-15-18 08:00AM  Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology GlobeNewswire
Aug-29-18 07:30AM  Kiniksa to Present Late-Breaking KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology GlobeNewswire +13.16%
Aug-28-18 04:01PM  Kiniksa Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference GlobeNewswire
Aug-06-18 07:30AM  Kiniksa Reports Second Quarter 2018 Financial Results and Pipeline Progress GlobeNewswire
Aug-02-18 04:01PM  Kiniksa Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jun-25-18 07:00AM  Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire -6.87%
Jun-14-18 04:01PM  Kiniksa Pharmaceuticals to Present at the JMP Securities 2018 Life Sciences Conference GlobeNewswire
Jun-12-18 02:36PM  Breaking Down Kiniksa Pharmaceuticals Ltds (NASDAQ:KNSA) Ownership Structure Simply Wall St.
May-29-18 04:57PM  Kiniksa Pharmaceuticals, Ltd. Announces Closing of Initial Public Offering GlobeNewswire -11.33%
May-24-18 06:51PM  Nasdaq Welcomes Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) to The Nasdaq Stock Market GlobeNewswire
May-23-18 09:13PM  Kiniksa Pharmaceuticals, Ltd. Announces Pricing of Initial Public Offering GlobeNewswire
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Patel Sanj KChairman & CEOMar 06Sale20.0033,115662,300212,570Mar 10 05:33 PM
Paolini John F.SVP & Chief Medical OfficerFeb 27Option Exercise1.8612,00022,32030,000Mar 02 05:48 PM
Paolini John F.SVP & Chief Medical OfficerFeb 20Option Exercise3.809,80337,25127,803Feb 21 04:57 PM
Paolini John F.SVP & Chief Medical OfficerFeb 20Sale18.969,803185,83218,000Feb 21 04:57 PM
Paolini John F.SVP & Chief Medical OfficerFeb 19Option Exercise3.8022,47785,41340,477Feb 21 04:57 PM
Paolini John F.SVP & Chief Medical OfficerFeb 19Sale18.2722,477410,65518,000Feb 21 04:57 PM
Paolini John F.SVP & Chief Medical OfficerFeb 14Option Exercise3.801,0393,94819,039Feb 18 06:05 PM
Beetham Thomas W.EVP & Chief Legal OfficerFeb 14Sale18.58591,09679,530Feb 19 05:24 PM
Paolini John F.SVP & Chief Medical OfficerFeb 14Sale18.331,03919,04518,000Feb 18 06:05 PM
Paolini John F.SVP & Chief Medical OfficerFeb 13Option Exercise3.8010,27739,05328,277Feb 18 06:05 PM
Paolini John F.SVP & Chief Medical OfficerFeb 13Sale18.2910,277187,96618,000Feb 18 06:05 PM
Paolini John F.SVP & Chief Medical OfficerDec 05Option Exercise1.868,00014,8808,000Dec 09 05:57 PM